Tags : Gastric Cancer

Biosimilars Regulatory

Henlius and Accord’s Zercepac (trastuzumab, biosimilar) Receive the EMA Approval

Shots: The approval is based on comparative quality studies, clinical studies including preclinical data and resulted in bio-similarity, comparable efficacy and safety of Zercepac (HLX02) vs Herceptin Zercepac is developed under NMPA and EMA biosimilar guidelines and has been evaluated with the reference trastuzumab including comparative quality studies, preclinical studies, a P-I clinical study and […]Read More


Genialis Collaborates with Oncologie on Precision Medicine Initiative in Gastric

Shots: The collaboration will combine Genialis’ expressions software platform and analytics IP with Oncologie’s clinical and translational expertise to refine patient stratification methodologies The companies will initially focus on modeling gene expression signatures predictive of treatment for gastric cancer. The methodology will further enhance Oncologie’s clinical development plans to expand beyond gastric cancer Genialis merges […]Read More


Roche Launches Ventana HER2 Dual ISH CDx for the Identification

 Shots: Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab) The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer The Ventana HER2 assay is fully automated on […]Read More